A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Efficacy and Safety Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease (MCI to Mild Dementia Due to AD)
The purpose of this study is to assess the efficacy and safety of trontinemab in participants with early symptomatic Alzheimer's disease (AD) (mild cognitive impairment [MCI] to mild dementia due to AD).
Inclusion Criteria:
Exclusion Criteria:
global-roche-genentech-trials@gene.com888-662-6728
Sherman Oaks, California 91403, United States
Chicago, Illinois 60640, United States
Springfield, New Jersey 07081, United States
C. A. B. A., C1055AAF, Argentina
Porto Alegre, Rio Grande do Sul 90610-000, Brazil
São Bernardo do Campo, São Paulo 09715-090, Brazil
Amiens Cedex1, 80054, France
Bordeaux, 33076, France
Berlin, 13125, Germany
Homburg/Saar, 66421, Germany
Perugia, Umbria 06156, Italy
?cinawa, 59-330, Poland
?ory, 44-240, Poland
?ód?, 92-216, Poland
B?dzin, 42-500, Poland
Bia?ystok, 15-756, Poland
Późna, 61-731, Poland